NEW YORK (GenomeWeb News) – Imaging company Definiens and the cancer treatment technology company Clarient have agreed to co-develop tools for evaluating cancer biomarkers, Clarient said today.
Under the terms of the five-year agreement, the companies will develop a series of image analysis tools that Clarient will use in its internal research programs and will also offer through its PathSite customer web portal.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.